Literature DB >> 7901140

DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

C Mura1, S Panserat, M Vincent-Viry, M M Galteau, E Jacqz-Aigrain, R Krishnamoorthy.   

Abstract

Deficient debrisoquine/sparteine type oxidation is inherited as an autosomal recessive trait. Of all Caucasians, 5-10% are poor metabolisers, due to the absence of cytochrome P4502D6. Extensive metabolisers (EMs) exhibit highly variable metabolic activity. We investigated the relationship between CYP2D6 activity and genotypes of the CYP2D locus in a large set of French Caucasian families. Genotypes concern both common mutations affecting the enzyme activity and linked BamHI polymorphisms of the locus. We found, like other authors, that in EMs part of the heterogeneity is explained by a subgroup of individuals heterozygous for a mutant allele. However, a second level of heterogeneity was detected among individuals not carrying mutations, and this was related to a polymorphic BamHI-defined DNA haplotype. Different combinations of haplotypes are associated with differences in CYP2D6 metabolic activity. This finding might help to clarify the conflicting data on the relation between CYP2D6 activity and susceptibility to lung cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901140     DOI: 10.1007/bf01247337

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  32 in total

1.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

Authors:  A K Daly; M Armstrong; S C Monkman; M E Idle; J R Idle
Journal:  Pharmacogenetics       Date:  1991-10

2.  NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.

Authors:  C Mura; J P Broyart; E Jacqz; J Elion; R Krishnamoorthy
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

3.  Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.

Authors:  W E Evans; M V Relling
Journal:  Mol Pharmacol       Date:  1990-05       Impact factor: 4.436

4.  Direct determination of dextromethorphan and its three metabolites in urine by high-performance liquid chromatography using a precolumn switching system for sample clean-up.

Authors:  N Motassim; D Decolin; T Le Dinh; A Nicolas; G Siest
Journal:  J Chromatogr       Date:  1987-11-27

5.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Authors:  M Eichelbaum; M P Baur; H J Dengler; B O Osikowska-Evers; G Tieves; C Zekorn; C Rittner
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 6.  P450 genes: structure, evolution, and regulation.

Authors:  D W Nebert; F J Gonzalez
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

7.  Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.

Authors:  N Caporaso; R B Hayes; M Dosemeci; R Hoover; R Ayesh; M Hetzel; J Idle
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

8.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

9.  Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

Authors:  C Mura; N Gerard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

10.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

View more
  5 in total

1.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 2.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

4.  Debrisoquine hydroxylation in a Polish population.

Authors:  P K Kunicki; D Sitkiewicz; A Pawlik; V Bielicka-Sulzyc; E Borowiecka; B Gawrońska-Szklarz; R Sterna; H Matsumoto; M Radziwoń-Zaleska
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacoz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.